Safety of direct oral anticoagulants in patients with liver disease: a systematic review and meta-analysis

References

• Decousus H, Tapson VF, Bergmann JF, et al. Factors at admission associated with bleeding risk in medical patients: findings from the IMPROVE investigators. Chest. 2011;139(1):69–79.
   PubMed Web of Science ®Google Scholar
• Monroe DM, Hoffman M. The coagulation cascade in cirrhosis. Clin Liver Dis. 2009;13(1):1–9.
   PubMed Web of Science ®Google Scholar
• Mahfood Haddad T, Hamdeh S, Kanmanthareddy A, et al. Nonalcoholic fatty liver disease and the risk of clinical cardiovascular events: a systematic review and meta-analysis. Diabetes Metab Syndr. 2017;Suppl 11:S209–S216.
   Google Scholar
• Turco L, de Raucourt E, Valla DC, et al. Anticoagulation in the cirrhotic patient. JHEP rep: innov hepatol. 2019; 1(3):227–239. 2020 February 11.
   PubMedGoogle Scholar
• Northup P, Reutemann B. Management of coagulation and anticoagulation in liver transplantation candidates. Liver Transplant. 2018;24(8):1119–1132.
   PubMed Web of Science ®Google Scholar
• Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. N Engl J Med. 2011;365(2):147–156.
   PubMed Web of Science ®Google Scholar
• Brunner R, Leiss W, Madl C, et al. Single-dose application of antithrombin as a potential alternative anticoagulant during continuous renal replacement therapy in critically ill patients with advanced liver cirrhosis: a retrospective data analysis. Anesth Analg. 2013;116(3):527–532.
   PubMed Web of Science ®Google Scholar
• Sasso R, Rockey DC. Anticoagulation Therapy in patients with liver cirrhosis is associated with an increased risk of variceal hemorrhage. Am J Med. 2019;132:758–766.
   PubMed Web of Science ®Google Scholar
• DeLeve LD, Valla DC, Garcia-Tsao G, et al. Vascular disorders of the liver. Hepatology. 2009;49(5):1729–1764.
   PubMed Web of Science ®Google Scholar
• Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149(2):315–352.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339(jul21 1):b2535.
   PubMed Web of Science ®Google Scholar
• Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–605.
   PubMed Web of Science ®Google Scholar
• Intagliata NM, Henry ZH, Maitland H, et al. Direct oral anticoagulants in cirrhosis patients pose similar risks of bleeding when compared to traditional anticoagulation. Dig Dis Sci. 2016;61(6):1721–1727.
   PubMed Web of Science ®Google Scholar
• Hum J, Shatzel JJ, Jou JH, et al. The efficacy and safety of direct oral anticoagulants vs traditional anticoagulants in cirrhosis. Eur J Haematol. 2017;98(4):393–397.
   PubMed Web of Science ®Google Scholar
• Goriacko P, Veltri KT. Safety of direct oral anticoagulants vs warfarin in patients with chronic liver disease and atrial fibrillation. Eur J Haematol. 2018;100(5):488–493.
   PubMed Web of Science ®Google Scholar
• Hanafy AS, Abd-Elsalam S, Dawoud MM. Randomized controlled trial of rivaroxaban versus warfarin in the management of acute non-neoplastic portal vein thrombosis. Vascul Pharmacol. 2018;113:86–91. Journal: Article in Press.
   PubMed Web of Science ®Google Scholar
• Nagaoki Y, Aikata H, Daijyo K, et al. Efficacy and safety of edoxaban for treatment of portal vein thrombosis following danaparoid sodium in patients with liver cirrhosis. Hepatol Res. 2018;48(1):51–58.
   PubMed Web of Science ®Google Scholar
• Pastori D, Lip GYH, Farcomeni A, et al. Incidence of bleeding in patients with atrial fibrillation and advanced liver fibrosis on treatment with vitamin K or non-vitamin K antagonist oral anticoagulants. Int J Cardiol. 2018;264:58–63.
   PubMed Web of Science ®Google Scholar
• Wang CL, Wu VC, Kuo CF, et al. Efficacy and safety of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with impaired liver function: a retrospective cohort study. J Am Heart Assoc. 2018;7(15):e009263. 2018 October 30.
   PubMed Web of Science ®Google Scholar
• Davis KA, Puleo CR, Kovalic AJ, et al. Efficacy and safety of direct oral anticoagulant therapy for the treatment of venous thromboembolism in patients with chronic liver disease. Thromb Res. 2019;176:27–29. 2019 February 16.
   PubMed Web of Science ®Google Scholar
• Lee HF, Chan YH, Chang SH, et al. Effectiveness and safety of non-vitamin K antagonist oral anticoagulant and warfarin in cirrhotic patients with nonvalvular atrial fibrillation. J Am Heart Assoc. 2019;8(5):e011112. 2019 March 06.
   PubMed Web of Science ®Google Scholar
• Lee SR, Lee HJ, Choi EK, et al. Direct oral anticoagulants in patients with atrial fibrillation and liver disease. J Am Coll Cardiol. 2019;73(25):3295–3308.
   PubMed Web of Science ®Google Scholar
• Qamar A, Antman EM, Ruff CT, et al. Edoxaban versus warfarin in patients with atrial fibrillation and history of liver disease. J Am Coll Cardiol. 2019;74(2):179–189. 2019 Jully 13.
   PubMed Web of Science ®Google Scholar
• Davis KA, Joseph J, Nisly SA. Direct oral anticoagulants and warfarin in patients with cirrhosis: a comparison of outcomes. J Thromb Thrombolysis. 2020;50(2):457–461.
   PubMed Web of Science ®Google Scholar
• Jones K, Pham C, Aguilar C, et al. Retrospective review on the safety and efficacy of direct oral anticoagulants compared with warfarin in patients with cirrhosis. Federal practitioner: health care pro VA, DoD, and PHS 2020; 37: 479–485. 2020 November 03.
   Google Scholar
• Serper M, Weinberg EM, Cohen JB, et al. Mortality and hepatic decompensation in patients with cirrhosis and atrial fibrillation treated with anticoagulation. Hepatology. 2020; DOI:10.1002/hep.31264.
   Web of Science ®Google Scholar
• Semmler G, Pomej K, Bauer DJM, et al. Safety of direct oral anticoagulants in patients with advanced liver disease. Liver Int. 2021;41(9):2159–2170.
   PubMed Web of Science ®Google Scholar
• Coons EM, Staubes BA, Casey AL, et al. Direct oral anticoagulants versus warfarin for treatment of thrombosis or atrial fibrillation in patients with cirrhosis: a retrospective cohort study. Ann Pharmacother. 2022;56(5):533–540.
   PubMed Web of Science ®Google Scholar
• Oldham M, Palkimas S, Hedrick A. Safety and efficacy of direct oral anticoagulants in patients with moderate to severe cirrhosis. Ann Pharmacother. 2022;56(7):782–790. 2021 September 24.
   PubMed Web of Science ®Google Scholar
• Yoo SY, Kim E, Nam GB, et al. Safety of direct oral anticoagulants compared to warfarin in cirrhotic patients with atrial fibrillation. Korean J Intern Med. 2022;37(3):555–566. 2022 January 27.
   PubMed Web of Science ®Google Scholar
• Steuber TD, Howard ML, Nisly SA. Direct oral anticoagulants in chronic liver disease. Ann Pharmacother. 2019;53(10):1042–1049.
   PubMed Web of Science ®Google Scholar
• Dibiasi C, Wiegele M, Gratz J. Orthotopic liver transplantation in a patient receiving apixaban for portal vein thrombosis. J Clin Anesth. 2019;56:41–42. 2019 January 27.
   PubMed Web of Science ®Google Scholar
• Haas S. New oral Xa and IIa inhibitors: updates on clinical trial results. J Thromb Thrombolysis. 2008;25(1):52–60.
   PubMed Web of Science ®Google Scholar
• Albertsen IE, Nielsen PB, Sogaard M, et al. Risk of recurrent venous thromboembolism: a Danish nationwide cohort study. Am J Med. 2018;131(9):1067–1074 e1064.
   PubMed Web of Science ®Google Scholar
• Kwon J, Koh Y, Yu SJ, et al. Low-molecular-weight heparin treatment for portal vein thrombosis in liver cirrhosis: efficacy and the risk of hemorrhagic complications. Thromb Res. 2018;163:71–76.
   PubMed Web of Science ®Google Scholar
• Bechmann LP, Sichau M, Wichert M, et al. Low-molecular-weight heparin in patients with advanced cirrhosis. Liver Int. 2011;31(1):75–82.
   PubMed Web of Science ®Google Scholar
• Kubisz P, Stanciakova L, Dobrotova M, et al. Apixaban - metabolism, pharmacologic properties and drug interactions. Curr Drug Metab. 2017;18(7):609–621.
   PubMed Web of Science ®Google Scholar
• Poulakos M, Walker JN, Baig U, et al. Edoxaban: a direct oral anticoagulant. Am J Health-system Pharm. 2017;74(3):117–129.
   PubMed Web of Science ®Google Scholar
• Kvasnicka T, Malikova I, Zenahlikova Z, et al. Rivaroxaban - metabolism, pharmacologic properties and drug interactions. Curr Drug Metab. 2017;18(7):636–642.
   PubMed Web of Science ®Google Scholar
• Lee KC, Hsu WF, Hsieh YC, et al. Dabigatran reduces liver fibrosis in thioacetamide-injured rats. Dig Dis Sci. 2019;64(1):102–112.
   PubMed Web of Science ®Google Scholar
• De Gottardi A, Trebicka J, Klinger C, et al. Antithrombotic treatment with direct-acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis. Liver Int. 2017;37(5):694–699.
   PubMed Web of Science ®Google Scholar